Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III factorial study of neoadjuvant TPF before chemoradiotherapy or radiotherapy plus cetuximab in locally advanced head and neck squamous cell carcinoma
2007-001938-14Phase 3Completed
- Sponsor
- AVAPO Ricerche
- Start
- May 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cisplatin, fluorouracil and cetuximab in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by AVAPO Ricerche. Primary endpoints: 3-year overall survival and Tolerability of concomitant chemoradiotherapy versus radiotherapy plus cetuximab. Started May 2008; status: completed.
02
Drugs
docetaxelcisplatinfluorouracilcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-001938-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001938-14.